Drug Trial Radar · NCT01242488
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
Last checked: Nov 20, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
Nov 2010
Primary completion
Jun 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Nov 17, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapy.
Conditions
- Rheumatoid Arthritis
Interventions
CDP6038Biological
60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
CDP6038Biological
120 mg sc at Weeks 0, 2, 4 6, 8, and 10
CDP6038Biological
240 mg sc at Weeks 0, 2, 4 6, 8, and 10
Tocilizumab (Actemra or RoActemra)Biological
8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
CDP6038Biological
60 mg sc at Weeks 0, 4 and 8
CDP6038Biological
240 mg sc at Weeks 0, 4 and 8
CDP6038Biological
120 mg sc at Weeks 0, 4 and 8
Placebo scOther
0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
Placebo scOther
0.9% Sodium chloride for injection at Weeks 2, 6 and 10
Placebo ivOther
0.9% Sodium chloride for injection at Weeks 0, 4 and 8
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the Disease Activity Score (C-reactive protein) [DAS28(CRP)] for CDP6038 and placeboTime frame: Baseline, Week 12
Locations
82 sites in 3 countries. Site status is shown where the registry gives one.
166
Mesa, Arizona
154
Paradise Valley, Arizona
118
Scottsdale, Arizona
103
Hot Springs, Arkansas
125
Jonesboro, Arkansas
127
Covina, California
148
La Jolla, California
184
Long Beach, California
177
Los Angeles, California
104
Palo Alto, California
149
Sacramento, California
158
San Diego, California
129
Santa Maria, California
164
Upland, California
107
Wildomar, California
141
Hamden, Connecticut
137
Norwalk, Connecticut
101
Trumbull, Connecticut
111
Lewes, Delaware
176
Aventura, Florida
186
Daytona Beach, Florida
151
DeBary, Florida
114
Jupiter, Florida
183
Pinellas Park, Florida
178
Sarasota, Florida
140
South Miami, Florida
157
Tampa, Florida
130
Gainesville, Georgia
162
Newnan, Georgia
153
Savannah, Georgia
113
Stockbridge, Georgia
116
Idaho Falls, Idaho
160
Moline, Illinois
156
Rock Island, Illinois
168
Springfield, Illinois
133
Cedar Rapids, Iowa
172
Kansas City, Kansas
185
Saint Clair Shores, Michigan
112
St Louis, Missouri
134
St Louis, Missouri
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.